The Globe and Mail Content from: 100 Years of Insulin report Published April 23, 2021
Flash glucose monitoring system improves diabetes management and strengthens virtual care.
As a family doctor, Dr. Richard Tytus has always had an interest in emerging technologies that make life better for his patients. He recently wrote a chapter of a book on the benefits of video medicine, and he believes that wearable health-monitoring devices can remove barriers to care.
“I love technology and I love engaging patients with technology,” says Dr. Tytus, who practises in downtown Hamilton and is an associate clinical professor of family medicine at McMaster University. “It’s so exciting to be a physician during these times.”
Wearable Continuous Ketone Monitoring Appears Feasible
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
3 Things to Cheer About in Abbott s Earnings Report
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Ask the Vet: Monitor Diabetic Pet’s Blood Sugar Levels at Home
Q: Pebbles, my 9-year-old terrier, was diagnosed with diabetes several months ago. I give her insulin injections and monitor her diabetes with urine test strips. Is there a better way to determine how well her diabetes is being controlled?
A: Diabetes mellitus arises most often in middle-aged dogs, usually around 7 to 9 years of age. Three-fourths of diabetic dogs are female.
Clinical signs include increased drinking and urination, increased appetite with decreased weight, and lethargy. Some diabetic dogs also develop cataracts and urinary tract infections.
While humans can experience different kinds of diabetes, dogs almost always have insulin-dependent diabetes, similar to type 1 diabetes in humans. In both forms, the pancreas does not produce insulin as it should.
Share this article
Share this article
ABBOTT PARK, Ill., April 20, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2021.
First-quarter sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis, which excludes the impact of foreign exchange.
First-quarter GAAP diluted EPS was $1.00 and adjusted diluted EPS, which excludes specified items, was $1.32, reflecting 103.1 percent growth versus the prior year.
1
Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of at least $3.74. Projected full-year adjusted diluted EPS from continuing operations of at least $5.00 remains unchanged and reflects growth of more than 35 percent versus the prior year.